Experienced in Deep Vein Thrombosis

Mingyue L. Cai

250 East Changgang Rd, 
Guangzhou, CN 
Experienced in Deep Vein Thrombosis
250 East Changgang Rd, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Mingyue Cai practices in Guangzhou, China. Cai is rated as an Experienced expert by MediFind in the treatment of Deep Vein Thrombosis. Their top areas of expertise are Splenic Infarction, Liver Cancer, Hypersplenism, and Deep Vein Thrombosis.

Their clinical research consists of co-authoring 39 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Deep Vein Thrombosis.

Locations

250 East Changgang Rd, Guangzhou, 510260, China
Other Locations
600 Tianhe Road, Guangzhou, 510630, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Donafenib Combined With Sintilimab for Advanced HCC: a Single-arm, Single-center, Prospective Study
Donafenib Combined With Sintilimab for Advanced HCC: a Single-arm, Single-center, Prospective Study
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: Donafenib+Sintilimab
Study Phase: Phase 2
Transcatheter Arterial Chemoembolization Combined With Lenvatinib and Sintilimab for Unresectable Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study
Transcatheter Arterial Chemoembolization Combined With Lenvatinib and Sintilimab for Unresectable Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Transcatheter Arterial Chemoembolization with Lenvatinib and Sintilimab
Study Phase: Phase 2
Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced Hepatocellular Carcinoma: A Prospective Study
Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced Hepatocellular Carcinoma: A Prospective Study
Enrollment Status: Unknown
Publish Date: September 23, 2021
Intervention Type: Drug
Study Drugs: Sintilimab, Bevacizumab
Study Phase: Phase 1
View 2 Less Clinical Trials

39 Total Publications

Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.
Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.
Journal: Journal of hepatology
Published: February 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cai's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile